Contera Pharma will receive an upfront payment and full research funding for each target under investigation
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
New study presents a human-relevant stress model for assessing potential therapeutics
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Takeda will seek an external partner to leverage its cell therapy platform technologies
IND application for EB-003 expected in early 2026
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Subscribe To Our Newsletter & Stay Updated
